BMY
Bristol-Myers Squibb Company
NYSE: BMY · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$55.67
+1.18% today
Updated 2026-06-05
Market cap
$111.21B
P/E ratio
15.25
P/S ratio
2.29x
EPS (TTM)
$3.57
Dividend yield
4.55%
52W range
$41 – $62
Volume
10.6M
WallStSmart proprietary scores
60
out of 100
Grade: C+
Hold
Investment rating
4.7
Growth
C4.5
Quality
C9.0
Profitability
A+6.0
Valuation
B6/9
Piotroski F-Score
Moderate
1.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$61.81
+11.03%
12-Month target
$67.13
+20.59%
Intrinsic (DCF)
$72.40
Margin of safety
+17.22%
4 Strong Buy6 Buy18 Hold1 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ ROE 36.25% — strong efficiency
+ Free cash flow $757.00M — positive
+ 17.22% below intrinsic value
Risks
- Altman Z 1.42 — distress zone
- Debt/equity 2.22x — high leverage
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $46.16B | $45.01B | $48.30B | $48.19B | $48.48B | $47.6B |
| Net income | $6.33B | $8.03B | $-8.95B | $7.05B | $2.68B | — |
| EPS | — | — | — | — | $3.57 | $6.33 |
| Free cash flow | $11.95B | $12.65B | $13.94B | $12.85B | $757.00M | — |
| Profit margin | 13.71% | 17.83% | -18.53% | 14.63% | 15.00% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-03 | SHORT, BARTIE WENDY | Sale | 8,040 | — |
| 2026-06-03 | SHORT, BARTIE WENDY | Buy | 8,040 | — |
| 2026-06-03 | SHORT, BARTIE WENDY | Sale | 3,876 | $54.72 |
Peer comparison
Smart narrative
Bristol-Myers Squibb Company trades at $55.67. representing a P/E of 15.25x trailing earnings. Our Smart Value Score of 60/100 indicates the stock is good. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 1.42, it sits in the distress. TTM revenue stands at $48.48B. with profit margins at 15.00%. Our DCF model estimates intrinsic value at $72.40.
Frequently asked questions
What is Bristol-Myers Squibb Company's stock price?
Bristol-Myers Squibb Company (BMY) trades at $55.67, on a P/E of 15.3x and a P/S of 2.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Bristol-Myers Squibb Company overvalued?
Bristol-Myers Squibb Company carries a Smart Value Score of 60/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $72.40 versus the $55.67 price, a 17.2% margin of safety on a cash flow basis.
What is the price target of Bristol-Myers Squibb Company (BMY)?
The 12-month analyst consensus target is $61.81, about 11.0% above the current $55.67. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of BMY by 2030?
Our research-backed model puts the 2030 base case at $286.08, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Bristol-Myers Squibb Company (BMY)?
Our DCF model estimates intrinsic value at $72.40, a +17.2% margin of safety versus today's $55.67. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Bristol-Myers Squibb Company's revenue?
Bristol-Myers Squibb Company's trailing twelve-month revenue is $48.48B, and our model projects it reaching about $50.50B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Bristol-Myers Squibb Company's Altman Z-Score is 1.42, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio2.29x
ROE36.25%
Beta0.26
50D MA$58.18
200D MA$53.06
Shares out2.04B
Float2.04B
Short ratio—
Avg volume10.6M
Performance
1 week+0.00%
1 month+0.47%
3 months-3.07%
YTD+6.17%
1 year—
3 years—
5 years—